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Summary
Carbamazepine (CBZ) overdose is a problem occasionally seen that could be fatal. In the event of intoxication, complications such as cardiac 
arrhythmia, breathing depression and neurologic symptoms can be noted, extending even to causing a coma. In this report, we present a 
22 year old epileptic patient who has an increased frequency of seizures due to high doses of CBZ. After noting the blood drug level as 24 
μgr/ml (normal range: 4-12), necessary precautions were taken to reduce the drug overdose. The CBZ dose was reduced, the seizures did 
not recur. The increased frequency of seizures does not necessarily indicate an inadequate drug dose in an epileptic patient; on the cont-
rary, it can be an indication of drug overdose.
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Özet
Karbamazepin (KBZ) doz aşımı zaman zaman karşılaşılan ve yaşamı tehdit edebilen bir problemdir. İntoksikasyon durumunda kardiyak arit-
mi, solunum depresyonu ve komaya kadar ilerleyebilen nörolojik belirtiler görülebilir. Burada tedavi amaçlı yüksek doz KBZ kullanımının 
arkasından nöbetleri sıklaşan 22 yaşında bir hasta sunduk. Hastanın ilaç kan düzeyi 24μgr/ml (Normal: 4-12) olarak saptandığında ilaç 
doz aşımına yönelik tedavisi başlandı, KBZ dozu azaltıldı. Tedavi sonrasında nöbetleri tekrarlamadı. Epileptik bir hastada nöbet sıklığının 
artması mutlaka yetersiz ilaç dozu anlamına gelmemelidir; tam tersine bu durum ilaç doz aşımının bir göstergesi de olabilir.
Anahtar sözcükler: Kan ilaç düzeyi; karbamazepin doz aşımı; epilepsi.
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Carbamazepine (CBZ) inhibits the secretion of glutamate 
and glutamate-like transmitters by blocking presynap-
tic voltage gated sodium channels in the central nervous 
system.[1] It also blocks N-methyl D-aspartate and adeno-
sine receptors. It has been used for the treatment of post-
herpetic neuralgia, phantom extremity pains, and manic 
depressive disorders, except in those patients undergoing 
treatment for epilepsy.[1,2] The therapeutic dosage of CBZ 
is 15-25 mg/kg and serum CBZ levels should be between 
4-12 μg/ml. Dizziness, headache, increase in epileptic ac-
tivity, diplopia, blurred vision, tremor, rigidity, dysarthria, 
and nystagmus are adverse effects that have been repor-
ted with overdose of this drug on the central nervous 
system.[1-3] To diminish gastrointestinal involvement during 
the treatment of overdose, activated charcoal is given to 
the patient at repetitive doses (at 4-6 hour intervals).[2] In 
the event of life-threatening conditions, activated charco-
al hemodialysis and hemoperfusion are applied.[4,5] Since 
high serum levels of CBZ can cause undesirable effects, the 
blood drug levels have to be controlled. 
Here, we present a case taking a high therapeutic dose of 
CBZ that resulted in an increased frequency of epileptic 
seizures. 
Case Report
A 22-year-old patient was admitted to our emergency 
clinic with seizures.  The patient had been under care for 
simple partial epilepsy for the past 21 years, had been 
receiving 2x500 mg CBZ treatment, and has had seizures 
less frequently than once a month. The patient’s relatives 
reported that he first had contractions on the right side 
followed by the left. These contractions lasted for nearly 
15 minutes, and he could communicate with them during 
the seizure. He did not clamp down on his teeth, had no 
salivation or staring, but he had had 3 seizures since the 
night before. The patient also had occasional complaints 
of diplopia. Two days earlier, the patient had come to our 
emergency clinic suffering a simple partial seizure lasting 
for one minute. At that time, the CBZ dose that he had been 
using, 2x400 mg was considered as inadequate and chan-
ged to 2x500 mg. On his present arrival to our emergency 
clinic, he was conscious, oriented, cooperative, and had 
mild mental retardation. The patient’s physical examinati-
on revealed that his blood pressure was 130/85 mmHg, his 
pulsation was 83/min rhythmic, his respiratory rate was 20/
min, and his body temperature was 36.6°C. An ECG exami-
nation revealed that the heart was at normal rhythm with 
a heart rate of 80/min. In a neurological examination, his 
pupillary was isochoric, his direct and indirect light reflexes 
were positive, and his eye movements were normal in all 
directions.  In a motor examination, his right arm exhibited 
slight weakness. Deep tendon reflexes were normoactive 
bilaterally. A blood analysis revealed that his leucocyte was 
4.850/mm3, hemoglobin was 15.1 g/dl, thrombocyte was 
229000/mm3, total protein was 6.4 g/dl (normal: 6.3-8.7), 
albumin was 3.4 g/dl (normal: 3.5-5.4), blood urea nitro-
gen was 7.1 mg/dl, creatinin was 0.84 mg/dl, sodium was 
134 mEg/L, potassium was 3.77 mEg/dL, AST was 20 U/L, 
and ALT was 8 U/L. Upon recurrence of focal motor seizure 
while in the emergency room, I.V. diazepam treatment was 
administered. When the patient’s blood CBZ levels reached 
24 μg/ml (normal level is 4-12 μg/ml), a combination of 
1000 cc Isotonic, 1000cc 5% Dextrose, and 100 mEq NaH-
CO3 was given to him, since the seizures were attributed to 
CBZ toxicity. 
A nasogastric catheter was applied to him for gastric dra-
inage, and then he was given activated charcoal (1 g/kg). 
The activated charcoal was administered in 4 hour inter-
vals a total of three times. In order to maintain the patient’s 
treatment and to regulate medicine doses, he was hospi-
talized in the neurology service. During the service follow-
ups, his CBZ dose was regulated to 2x300 mg, and his se-
rum CBZ level, which was checked a few days later, was 
determined to be 12 μg/ml. The patient had no seizures 
and a normal EEG during the follow-up, and was dischar-
ged from the hospital. 
Discussion
Carbamazepine is an antiepileptic drug that has tricyclic 
content. It has been used for the treatment of partial and 
generalized epilepsies, bipolar affection disorder, trigemi-
nal neuralgia, postherpetic neuralgia, and phantom extre-
mity pains. It inhibits sodium channels that are responsive 
to presynaptic voltage in the central nervous system. Be-
cause of the drug’s lipophilic content, it is absorbed diffe-
rently based on oral intake. It can reach plasma crest levels 
within 6-8 hours, and these levels can remain for up to 24 
hours. After it is taken orally, it quickly passes to the brain 
because of its high lipid solubility.[1-3] 
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referenced chronic adverse effects. Symptoms and fin-
dings are contingent upon the dose and are proportional 
to the serum levels. Symptoms are often neurologic may 
change depending upon absorption from the gastrointes-
tinal system.[2,3]
Many sources report that doses over 40 mg/kg are fatal.[1-3] 
While symptoms are generally neurologic (ataxia, nystag-
mus, mydriasis, movement disorders, anticholinergic to-
xidermia) for amounts taken over 20 mg/kg, doses over 
50 mg/kg can lead to central nervous system problems 
such as unconsciousness, coma, seizure and cardiotoxi-
city, which can progress and become fatal.[3,4] The protein 
and albumin levels in our patient were close to the lower 
border line. In patients with lower protein and albumin le-
vels, the toxic signs of CBZ and its active metabolites ‘CBZ 
10,11-epoxid’  might be seen even for the lower doses, sin-
ce both are highly bound to plasma proteins.[1,2,6]
Plasmapheresis is a technique that gives successful results 
and has recently been used for CBZ overdose.[7] For CBZ 
overdose, hemoperfusion and hemodialysis are recom-
mended when supportive care is unattainable, and coma, 
seizure, and cardiovascular risks are high (serum CBZ level 
>50 mg/L).[8-11] Because the blood drug level was not high 
in our patient, hemoperfusion and hemodialysis were not 
needed.    
The CBZ dose used for our patient was 1000 mg/day. For 
such a patient, development of neurological symptoms can 
be possible. The patient’s blood drug level was 24 μg/ml, 
and he had increasingly frequent epileptic seizures. CBZ-
induced hyponatremia and seizures have been well desc-
ribed before.[12] However, the sodium levels were within 
normal ranges in our patient. CBZ is a powerful anticholi-
nergic drug, and therefore, increased seizures may occur as 
a result of the anticholinergic effect. This is most likely be-
cause this type of drug causes a blockade of the inhibitory 
presynaptic acetylcholine receptors, which are of the nico-
tinic type. This blockade would interrupt the normal feed-
back/control mechanism and allow for continued release 
of transmitters into the synapse.[6,13] In addition, CBZ is also 
an inhibitor of the central nervous system adenosine re-
ceptors. In case of massive overdose, the A2a receptor may 
lose selectivity. CBZ may inhibit A2a as well, behaving like 
the known adenosine receptor inhibitors theophylline and 
caffeine. Inhibition of adenosine receptors may cause the 
removal of the body’s natural anticonvulsant mechanism.[6]
With repetitive activated charcoal, the amount of drug pe-
netrating to the enterohepatic circulation was kept at a mi-
nimum level, and therefore other possible adverse effects 
on the central nervous system and a need for intensive 
care were prevented.[3]  
It is important to note that changing the treatment dose 
will not be a correct implementation without considering 
blood drug level of patients under CBZ treatment. Neurolo-
gical findings obtained from patients who use CBZ must be 
taken into consideration. The amount of medicine that has 
been taken, the measured serum CBZ level, and symptoms 
and treatment findings must be used to determine further 
diagnosis and treatment. For example, evaluating an epi-
lepsy patient in the emergency room, his/her blood drug 
level must be checked, rather than just increasing the dose, 
supposing that the medicine is at inadequate level. When 
the CBZ level is over 50 μg/ml, which has been considered 
to be fatal for the patient, a constant analysis of drug blood 
level is of vital importance. 
The reasons for increased epileptic seizure frequency have 
been investigated in practice. However, at clinics, a drug 
overdose has to be considered, and the blood level and 
dose of all medicines that the patient is using must be eva-
luated together. 
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